Angiotensin-converting Enzyme Inhibitor clinical trials at UCSF
1 in progress, 0 open to eligible people
ACEi ARB Withdrawal in CKD Patients
Sorry, in progress, not accepting new patients
The American Heart Association guidelines for high blood pressure (BP) currently recommend using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) as first-line therapy for patients with chronic kidney disease (CKD) stage 3 or above. However, the prevalence of ACEi and ARB use in patients with CKD stage 4 or 5 is low, and current BP guidelines acknowledge the lack of solid evidence to support the benefit of using these agents in advanced CKD.This study seeks to conduct a pilot trial to determine the safety and feasibility of ACEi and/or ARB continuation (intervention) versus withdrawal (control) in patients with advanced CKD.
San Francisco, California
Our lead scientists for Angiotensin-converting Enzyme Inhibitor research studies include Elaine Ku.
Last updated: